NY-UPTIME-INSTITUTE
3.2.2023 14:02:36 CET | Business Wire | Press release
Uptime Institute, the Global Digital Infrastructure Authority, a Dominus Capital, L.P. portfolio company, announced today that it has completed its acquisition of Academia Group Limited and all of its global subsidiaries including CNet Training, Ltd.
CNet Training, located in Bury Saint Edmunds, Suffolk, England, is an International award-winning technical education company. CNet Training has been designing and delivering professional network and data center infrastructure training programs since 1996 and has trained over 83,000 data center professionals across 45 countries.
“The data center industry is one of the fastest growing markets in the world. The continued, extraordinary industry expansion requires a growing and diverse workforce, however concerns over the industry’s ability to attract, educate, and retain skilled technical staff persist. This acquisition will help our respective customers thrive in a rapidly changing ecosystem, by giving them access to a range of world class corporate learning and development technical education programs that are backed up by practical experience and specialized domain expertise,” said Martin V. McCarthy, CEO, Uptime Institute.
CNet Training dramatically extends the range and depth of Uptime Education offerings and positions Uptime as the Learning & Development partner of choice around the world. The combined offerings will include solutions valuable for every point in a career for a digital infrastructure professional. This includes entry level staff, even adolescents in apprenticeships, to post graduate degrees in Data Center Leadership for savvy, long serving professionals.
“We are excited to join the accelerating Uptime team. CNet Training was already growing quickly, but now will have many more opportunities through further geographic expansion, and new service offerings, as a part of Uptime. As we look forward to this next phase, I want to personally thank all our clients, staff, and investors who have supported us over these past 26 + years of delivering unique value and in bringing ongoing innovation to the Digital Infrastructure Education market,” said Andrew Stevens, CEO of CNet Training.
Uptime Institute’s Intelligence team recently completed a market research study indicating the number of staff needed to design, build, and operate data centers will continue to grow globally from about 2.0 million in 2019 to nearly 2.3 million by 2025. A wide range of specialist jobs (230 detailed in Uptime Institute Data Center Career Pathfinder, developed in association with Google, Meta & Microsoft) are required by the sector to support its continued expansion. The combination of Uptime Institute and CNet Training will directly address the evolving training needs of all current and future data center employees as they progress through their careers.
Bob Haswell, Founding Partner at Dominus Capital, added, “This first acquisition for Uptime under Dominus ownership will further establish Uptime Education as the unparalleled leader in Digital Infrastructure Education around the world. Uptime is the undisputed market leader worldwide, with results-oriented solutions for both providers and consumers of services delivered through mission critical data center, the true digital foundries, and factories of the Internet economy. The ongoing availability, resiliency, sustainability, security, and business value of these key infrastructure building blocks still overwhelmingly depend on the quality and capabilities of the workforces that operate them, and the skill, training and education of each individual team member.”
Uptime Institute continues to identify and assess potential add-on acquisitions to broaden its offering and continue to execute on its mission to help data center owners, operators, and tenants ensure resilient, available, sustainable, and secure digital infrastructure.
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. For over 25 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers – the backbone of the digital economy. With its Tier Standard and Certifications, Management & Operations reviews, SCIRA-FSI financial sector risk assessment, broad range of additional risk and performance assessments, Intelligence research services, and accredited training courses completed by over 10,000 data center professionals, Uptime has helped thousands of companies in over 100 countries to optimize critical IT assets while managing costs, resources, and efficiency.
Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, KSA Singapore, and Taipei. For more information, please visit www.uptimeinstitute.com.
About CNet Training
CNet Training (CNet) has been delivering technical education programs since 1996. Today CNet is the global leader in technical education for the digital infrastructure industry, comprising the data center and network infrastructure sectors and is the only industry dedicated education provider to award both internationally recognized qualifications and professional certifications. A significant part of CNet Training ’s history is the development of the highly acclaimed Global Digital Infrastructure Education Framework, which offers industry professionals an opportunity to plan technical education, qualifications, and certifications to meet on-going individual and business needs.
Since CNet’s inception it has delivered training across 218 delivery locations in 45 countries and in 19 time zones. Over 83,000 individuals of 153 different nationalities have accessed CNet Training’s technical education. For more information, please visit www.cnet-training.com
About Dominus Capital, L.P.
Based in New York, Dominus Capital is a leading middle-market private equity investment firm focused on management-led buyouts and growth capital investments in family-owned and founder-operated companies in the business services and light manufacturing sectors. Drawing on the experience, knowledge and network of its founders and a team of in-house operating executives, Dominus works hand-in-hand with exceptional management teams to unlock the untapped potential of its portfolio companies. Recently named one of the top 50 middle market private equity firms, Dominus takes a long-term approach to investing and has a consistent and highly successful track record of achieving significant growth at its portfolio companies. The Dominus team has executed more than 90 transactions over the past 20+ years. For more information, please visit www.dominuscap.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
